Souhaitez-vous accéder aux communiqués récents ?

Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Alyssa Levin appointed to Board of Directors and as Chair of the Audit CommitteeClara Cambon-Thiebaud joins as VP, Regulatory...

New publication identifies neuromuscular junction transmission failure as a novel mechanism contributing to sarcopenia, with preclinical studies showing that ClC-1 inhibition improves neuromuscular...

MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced a strategic reorganisation of its operations and...

Vivasor Appoints JP3E Development as Exclusive Strategic Representative in the Republic of Korea

CALGARY, AB, July 21, 2026 (GLOBE NEWSWIRE) -- Seegnal Inc. (TSXV: SEGN) (“Seegnal” or the “Company”), a global leader in SaaS clinical division support solutions, is announcing an extension to its...

A synthetic recombinant PRP is the next phase of our strategic plan in building a new therapeutic drug class aimed at treating a range of chronic diseases

European Patent Office confirms patent protection for SOT201, next-gen PD-1-targeting immunocytokine currently being evaluated in a Phase 1 clinical trial

SYDNEY, July 20, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) today announces that results from its proof-of-concept trial, entitled “A phase 2 randomised, double-blind,...

FLORHAM PARK, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for...

BEIJING, July 16, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced...